NIAID Banner Logo Image

HIV Drugs in Development


Drug ClassCompanyDrug NameAlt NameDrug StatusNotesAIDS#
Biological Response Modifier Hemispherx; Rega Institute For Medical ResearchAtvogen™Ampligen, AMP, Poly(I)-Poly(C12U)Phase 2Completed 000136
CombinationMylanTLE400Tenofovir Disoproxil Fumarate and Lamivudine and EfavirenzNew Drug Application (NDA) filing expected in 2016  
CombinationGlaxoSmithKlineTivicay™ and Epivir™ Dolutegravir and LamivudinePhase 1Recruiting 
CombinationGlaxoSmithKlineTivicay™ and Edurant™ Dolutegravir and RilpivirinePhase 3Ongoing 
CombinationTibotec PharmaceuticalsPrezista™ and Emtriva™ and Tybost™ and Tenofovir AlafenamideDarunavir and Emtricitabine and Cobicistat and Tenofovir AlafenamidePhase 3Recruiting 
CombinationMerckMK-1439ADoravirine and Lamivudine and Tenofovir Disoproxil FumaratePhase 3Ongoing 
CombinationGilead SciencesBictegravir and Emtriva™ and Tenofovir AlafenamideBictegravir and Emtricitabine and Tenofovir AlafenamidePhase 3Recruiting 
Entry and Fusion InhibitorPfizerPF-00232798 Phase 2Completed 
Entry and Fusion InhibitorIncyte CorporationINCB-009471INCB-9471Phase 2Completed 503495
Entry and Fusion InhibitorTanox; Biogen Idec; Taimed BiologiesIbalizumabTNX-355; Hu5A8Phase 3Recruiting 209859
Entry and Fusion InhibitorBristol-Myers SquibbFostemsavirBMS-663068; prodrug of BMS-626529Phase 3Recruiting 
Entry and Fusion InhibitorTobira TherapeuticsCenicrivirocTBR-652; TAK-652Phase 2Completed 224423
Entry and Fusion InhibitorGenzyme CorporationAMD-070AMD-11070Phase 1/2Completed 495149
Entry and Fusion InhibitorRapid PharmaceuticalsAdaptavirRAP101; monomeric d-Ala-peptide T-amide (mDAPTA)Phase 2Unknown 052004
Entry and Fusion InhibitorCytoDyn, Inc.; Progenics PharmaceuticalsPRO-140 Phase 2/3Recruiting 088103
Entry and Fusion InhibitorMerck (Schering-Plough)VicrivirocSCH-417690, SCH-D, VCVPhase 3Completed 210504
Entry and Fusion InhibitorSangamo BioSciencesSB-728-T Phase 1/2Ongoing 
Entry and Fusion InhibitorSangamo BioSciencesSB-728-HSCSB-728mR-HSPCPhase 1Recruiting 
Histone Deacetylase (HDAC) InhibitorAbbott LabsEpival™; Depakote™Valproic Acid (VPA), Divalproex SodiumPhase 2Unknown 057177
Histone Deacetylase (HDAC) InhibitorMerckZolinza™Vorinostat; MK-0683, Suberoylanilide Hydroxamic Acid (SAHA)Phase 1/2Completed 186714
ImmunomodulatorMologen; University of AarhusLefitolimodMGN-1703Phase 1/2Ongoing 
ImmunomodulatorAmgenEnbrel™Etanercept; p75 TNFR-Fc fusion proteinPhase 2Completed 
ImmunomodulatorPfizer (Wyeth)Ammonium Trichlorotellurate; OssireneAS-101Phase 2Completed 000042
ImmunomodulatorHoffmann-La RochePegasys™PEG IFN alpha-2aPhase 2Completed 
ImmunomodulatorGlaxoSmithKlineTucaresol Phase 2Completed 029800
Integrase InhibitorBoehringer IngelheimBI-224436 Phase 1Completed 566575
Integrase InhibitorJapan Tobacco Inc.; Gilead SciencesElvitegravirEVG, GS-9137, JTK-303Phase 2/3Ongoing 241767
Integrase InhibitorGlaxoSmithKlineCabotegravirGSK1265744; S-265744 Phase 2/3Not Yet Recruiting 
Integrase InhibitorGilead SciencesBictegravirGS-9883Phase 3Recruiting 
Integrase InhibitorGlaxoSmithKlineGSK1247303 Phase 1Terminated 
Maturation InhibitorBristol-Myers SquibbBMS-9551763532795Phase 2Recruiting 
Maturation InhibitorGlaxoSmithKlineGSK2838232 Phase 1Recruiting 
MicrobicideReprotect, Inc.BufferGel™Carbomer 974P, Carbopol 974P, Carbopol PolymerPhase 2Completed 180064
MicrobicideMyrexis, Inc.; Panacos PharmaceuticalsBevirimatBVM, PA-457; MPC-4326Phase 2Completed 028530
MicrobicidePopulation Council Center for Biomedical ResearchCarraguard™Carragaen, Carrageenan Gum, Carrageenin, Irish Moss Extract, PC-515Phase 3Completed 000100
MicrobicideTibotec Pharmaceuticals; Janssen; Johnson & JohnsonDapivirineTMC-120Phase 3Completed 105293
MicrobicideProcept/Interneuron/IndevusPro-2000PRO-2000/5Phase 3Completed 032942
MicrobicideGilead SciencesTenofovir Gel (GS-1278)GS-1278; PMPA GelPhase 3Completed 021800
MicrobicideUniroyal/Crompton Corp/BiosynUC781 Phase 1Completed 029940
MicrobicideStarpharmaVivaGel™SPL-7013 GelPhase 1/2Completed 223863
NNRTIMerck & CoDoravirineMK-1439Phase 3Recruiting 525576
NNRTIBoehringer IngelheimBILR 355 BS Phase 2Terminated 212773
NNRTIGlaxoSmithKlineGSK2248761IDX-899Phase 2Completed 485324
NNRTIPfizerLersivirineUK453,061Phase 2Terminated 497274
NNRTIKainos MedicineKM-023 Phase 1Completed 
NRTIPharmasset/Dupont Pharmaceuticals; VionReverset™Dexelvucitabine; DFCPhase 2Completed 000572
NRTIGlaxo Wellcome; GlaxoSmithKline; Pharmasset, Inc.RacivirRCV; (+/-) FTCPhase 2Completed 005245
NRTIRFS Pharma; Biochem Pharma; Triangle Pharmaceuticals; Gilead SciencesAmdoxovirDAPDPhase 2Completed 005431
NRTIAvexaApricitabine(-)-Dotc; ATC; AVX-754; BCH-10618; BCH-10619; BCH-10652; SPD-754Phase 3Withdrawn 058066
NRTIKoronisKP-1461 KP-1461 (prodrug of KP-1212)Phase 2Terminated 293211
NRTIChimerixCMX-157 Hexadecyloxypropyl ester of TenofovirPhase 1/2Recruiting 477886
NRTIGilead SciencesGS-7340Tenofovir Alafenamide (Prodrug of tenofovir)Phase 3Completed 046774
NRTIAchillion Pharmaceuticals; Vion PharmaceuticalsElvucitabineACH-126443; beta-L-Fd4CPhase 2Completed 060327
NRTIOncolys BioPharma; Brisol-Myers SquibbCensavudine; (renaming of Festinavir)4'-ethynyl-d4T; BMS-986001; OBP-601Phase 2Terminated 209894
Protease InhibitorTibotec PharmaceuticalsTMC-310911 Phase 2Completed 483146
Protease InhibitorConcert PharmaceuticalsC-10299 Phase 1Completed 
Protease InhibitorConcert PharmaceuticalsC-10297 Phase 1Completed 
Protease InhibitorConcert PharmaceuticalsC-10276 Phase 1Completed 
Rev InhibitorAbivax S.AABX464 Phase 2Recruiting 516635
UnidentifiedMerckMK-1972 Phase 1Terminated 
Viral Nuclear Export InhibitorKaryopharm TherapeuticsVerdinexorKPT335Phase 1Completed 

Last Updated: April 2017